ALSO NOTED: Merck gets OK for new type of HIV drug; Hycamtin is approved; Labopharm appeals FDA decision; and much more...

> The FDA has approved Merck's Isentress for HIV. This is a new type of drug, which prevents HIV from inserting its DNA into human DNA, stunting its ability to infect cells. Release

> The FDA has approved GlaxoSmithKline's Hycamtin for lung cancer. Release

> Labopharm has formally appealed its second approvable letter from the FDA on its once-daily formulation of tramadol. Release

> In response to an FDA approvable letter, Pozen has submitted more data on its migraine drug Trexima. Report

> Gene Logic has sold its genomics assets to India's Ocimum Biosolutions for $10 million. Report

> The FDA has granted Innovive orphan drug status for Tamibarotene, an experimental treatment for adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid and arsenic trioxide. Release

> The FDA has lifted its clinical hold on Telik's clinical trials for the cancer drug Telcyta. Release

> The new Sanofi CEO has some radical idea. In his first interview since taking the helm at Sanofi-Aventis, CEO Gérard Le Fur (photo) told the Financial Times that drug makers ought to cut prices and rely on volume for profits. Report

> Pharma is one of few industries where patent law doesn't inspire a yawn. So when the U.S. Patent Office introduced unfriendly rules governing patent continuations--vital to protecting brand-name meds--GlaxoSmithKline was first in line to sue. Report

> Pfizer is crashing an online party for physicians. The drug maker has inked a deal with Sermo, a sort of Facebook for docs who want to gossip about their practices--drug side effects included. Report

And Finally… Early detection and improved therapies are getting most of the credit for an accelerating decline in the United States' cancer death rate. Article

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.